Devatis
Devatis is a privately held pharmaceutical manufacturer and distributor of generic prescription medicines across 12 therapeutic areas, operating through 12 wholly-owned country entities on 4 continents and serving physicians, pharmacists, hospitals, and healthcare systems under US FDA and EU GMP standards.
- Company typePrivate
- Founded2007
- HeadquartersSan Clemente, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Devatis does
Devatis is a privately held pharmaceutical manufacturer and distributor operating a portfolio of generic prescription medicines across 12 therapeutic areas — spanning cardiopulmonary, cardiovascular, CNS, dermatology and immunology, digestive system and metabolism, oncology and hematology, respiratory, sensory organs (ophthalmology), and systemic anti-infectives — and distributed across 12 wholly-owned country entities on 4 continents (Oceania, Europe, North America, Latin America, Asia). Products are manufactured in facilities aligned with US FDA and EU GMP standards, with additional compliance under Swissmedic in Switzerland, supporting cross-jurisdictional market access. The group is the international affiliate network of Turkish pharmaceutical manufacturer Deva Holding A.Ş., with founding operations traced to DEVATIS LTD in New Zealand in 2007 and progressive expansion into Germany (2014), USA (2015), Switzerland (2018), Mexico (2019), Australia and Canada (2020), Serbia (2023), Netherlands and Azerbaijan (2024), and the UK and Austria (2025).
The company commercializes through country-specific direct sales teams engaging physicians, specialists, pharmacists, hospitals, and healthcare systems, augmented by distributor and channel partner relationships (e.g., Mexico ophthalmology distribution at Facofest congress) and a digital supply-chain backbone via TraceLink's MINT network linking order capture, warehouse execution, shipment visibility, and invoicing across wholesalers and 3PL providers. Marketing is concentrated on medical congress presence (ASHP Midyear, DCAT Week, ECRM, FAH, SGDV, Swiss Rheumatology, Mexican Ophthalmology Congress), proprietary content (Pharma Pulse magazine in Switzerland), and CEO-led PR in medical and national media. Revenue is generated through one-time pharmaceutical product sales via standard distribution and healthcare procurement channels; pricing is not publicly disclosed and is negotiated bilaterally. No external funding rounds, institutional investors, or public listing have been disclosed.
Deva Holding A.Ş. is identified as the ultimate parent entity, providing manufacturing and capital backing to the country-level subsidiaries. Group leadership is concentrated in Chairman & CEO Philipp D. Haas. Operational scale disclosures are limited — the listed headcount of 1–10 is inconsistent with a 12-country, multi-therapeutic-area operation and likely reflects incomplete firmographic data rather than actual employee count. Disclosed revenue figures are not available in the source material.
Devatis firmographics
Firmographics- Name
- Devatis
- Legal name
- Devatis
- Website
- https://devatis.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Devatis is a privately held pharmaceutical manufacturer and distributor of generic prescription medicines across 12 therapeutic areas, operating through 12 wholly-owned country entities on 4 continents and serving physicians, pharmacists, hospitals, and healthcare systems under US FDA and EU GMP standards.
- Ownership category
- akta.pro rank
Devatis industry classification
Industry- Product category
- Generic Pharmaceuticals Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)
- akta.pro secondary industry
- Direct-to-Provider / Clinic Buy-and-Bill Distributors (HLAIAJAM)
Keywords
Where Devatis is headquartered
LocationHeadquarters
- HQ city
- San Clemente
- HQ country
- United States
- HQ region
- North America
Offices12 records
Markets served
Devatis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Devatis generates revenue through the sale of prescription pharmaceutical products across 12 therapeutic areas. Products are manufactured in FDA and GMP-compliant facilities and distributed through direct sales teams and channel partners across global markets.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Devatis product offering
Product offeringCore offering
Devatis manufactures and distributes a broad portfolio of prescription pharmaceutical products across 12 therapeutic areas—including Cardiovascular System, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory System, Sensory Organs (Ophthalmology), and Systemic Anti-Infectives—for healthcare professionals, hospitals, and pharmacy chains across 12 countries. Products are produced in facilities aligned with US FDA and EU GMP standards and delivered through direct sales teams and channel partners.
Product overview
Devatis is a pharmaceutical company that operates as a single unified product offering—a broad portfolio of prescription medicines distributed across 12 therapeutic areas and 12 countries. The portfolio spans Cardiovascular, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory, Ophthalmology (Sensory Organs), Systemic Anti-Infectives, and other therapeutic areas. Products are manufactured in US FDA and EU GMP-compliant facilities, ensuring consistent quality and safety. The company also publishes Pharma Pulse, a magazine distributed to healthcare professionals in Switzerland.
Differentiator
Problem solved
Functional benefit
Products and services
- Pharmaceutical Products Portfolio Broad portfolio of prescription medicines across 12 therapeutic areas including Cardiovascular System, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory System, Sensory Organs (Ophthalmology), Systemic Anti-Infectives, and other areas. Manufactured in facilities aligned with US FDA and EU GMP standards and sold to healthcare professionals, hospitals, and pharmacy chains across 12 countries.
- Mexico's First Fusidic Acid Product A fusidic acid pharmaceutical product introduced by Devatis in Mexico as the first of its kind in the country, targeted at the ophthalmology therapeutic area and launched at the Facofest congress for ophthalmology professionals.
Companies that use Devatis
Customer profileSegments3 records
Ideal customer profiles2 records
Devatis technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Devatis partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- TraceLinkcoreDevatis has gone live on TraceLink's Multienterprise Information Network Tower (MINT) to digitize its end-to-end order-to-cash operations. This centralized network model replaces fragmented point-to-point EDI integrations, linking order capture, warehouse execution, shipment visibility, invoicing, and financial reconciliation across trading partners including wholesalers and 3PL providers. The implementation reduces new partner onboarding timelines from months to as little as three days and establishes the data foundation required for future AI agent-driven automation in supply chain monitoring.
Scale indicators3 records
Recent moves15 records
Expansion highlights6 records
Devatis competitors and assessment
Company assessmentDirect peers
- Apotex: Canadian-headquartered generic pharmaceutical manufacturer with vertically integrated operations and international reach; comparable to Devatis in manufacturing integration and broad generic portfolio across multiple therapeutic areas.
- Dr. Reddy's Laboratories: Global integrated pharmaceutical company offering generics, biosimilars, and APIs across multiple therapeutic areas with strong presence in North America, Europe, and emerging markets; matches Devatis's international, vertically integrated generic pharma profile.
- Stada Arzneimittel: German-headquartered generic pharmaceutical company with a broad European and international footprint across multiple therapeutic areas, very similar profile to Devatis's vertical integration, multi-country presence, and focus on off-patent molecules.
- Glenmark Pharmaceuticals: India-based global pharmaceutical company with a generics portfolio spanning multiple therapeutic areas and a presence in the US, Europe, and emerging markets; directly comparable in business model and international distribution footprint.
- Aurobindo Pharma: Indian-headquartered global generic pharmaceutical manufacturer with extensive international distribution; directly comparable to Devatis in product breadth, vertical integration, and multi-country commercial presence.
- Hikma Pharmaceuticals: Multinational generic and specialty pharmaceutical manufacturer with strong distribution across MENA, Europe, and North America; comparable to Devatis in product breadth, geographic diversification, and FDA/EU GMP manufacturing.
- Alvogen: Privately-held global generic pharmaceutical company with operations across the US, Europe, and Asia; comparable to Devatis in product breadth, multi-country footprint, and vertically integrated generics distribution model.
- Lupin Pharmaceuticals: Indian-headquartered global pharmaceutical company with strong US presence and broad generic portfolio across therapeutic areas; comparable to Devatis in international distribution model and generic focus.
Broad incumbents
- Viatris: Global pharmaceutical powerhouse formed from Mylan and Upjohn, offering an extensive generic and branded portfolio across virtually all therapeutic areas; significantly larger than Devatis but competes in the same generic distribution channels worldwide.
- Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with operations in nearly every country and a portfolio spanning virtually every therapeutic area; a much larger incumbent competing in the same generic distribution channels as Devatis.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Devatis social profiles
Digital presenceDevatis compliance and trust
Trust signalCompliance5 records
Devatis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Devatis leadership team
Management profileNumber of profiles
Profiles1 record
Devatis subsidiaries and ownership
Company hierarchySubsidiaries12 records
Devatis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Devatis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Devatis
What does Devatis do?
Devatis manufactures and distributes a broad portfolio of prescription pharmaceutical products across 12 therapeutic areas—including Cardiovascular System, Central Nervous System, Dermatology and Immunology, Digestive System and Metabolism, Oncology and Hematology, Respiratory System, Sensory Organs (Ophthalmology), and Systemic Anti-Infectives—for healthcare professionals, hospitals, and pharmacy chains across 12 countries. Products are produced in facilities aligned with US FDA and EU GMP standards and delivered through direct sales teams and channel partners.
Is Devatis a public or private company?
Devatis is a private company. It is classified as corporate owned and is currently operating.
When was Devatis founded?
Devatis was founded in 2007. It employs 1 to 10 people.
Where is Devatis based?
Devatis is headquartered in San Clemente, United States, in the North America region.
How does Devatis make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Devatis's main competitors?
Direct peers on record are Apotex, Dr. Reddy's Laboratories, Stada Arzneimittel, Glenmark Pharmaceuticals, Aurobindo Pharma, Hikma Pharmaceuticals, Alvogen and Lupin Pharmaceuticals. Broad incumbents are Viatris and Teva Pharmaceutical Industries.
Does Devatis have an API?
No public API is recorded for Devatis.
What industry is Devatis in?
Devatis's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution, with a secondary code of HLAIAJAM, Direct-to-Provider / Clinic Buy-and-Bill Distributors. Its NAICS code is 325412 and its SIC code is 5122.